Design Therapeutics, Inc. (DSGN)
| Market Cap | 785.09M +366.5% |
| Revenue (ttm) | n/a |
| Net Income | -69.79M |
| EPS | -1.22 |
| Shares Out | 61.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 193,605 |
| Open | 12.48 |
| Previous Close | 12.53 |
| Day's Range | 12.47 - 13.15 |
| 52-Week Range | 3.11 - 13.54 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 15.25 (+19.8%) |
| Earnings Date | May 8, 2026 |
About DSGN
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ sys... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DSGN stock is "Strong Buy." The 12-month stock price target is $15.25, which is an increase of 19.80% from the latest price.
News
Design Therapeutics Transcript: Leerink Global Healthcare Conference 2026
RESTORE-FA is progressing with key data expected in the second half of the year, while exploratory studies in FECD and DM1 advance using the GeneTAC platform. The company is well-funded into 2029, aiming for clinical proof of concept in major indications.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
Design Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company presented updates on its small molecule genetic medicine platform, highlighting clinical progress in FA, FECD, and DM1. Key data readouts are expected in the second half of this year and next year, with strong financial resources supporting ongoing trials.
Design Therapeutics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to...
Design Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing small molecule therapies for monogenic diseases, with clinical programs in Friedreich's ataxia, Fuchs' corneal dystrophy, and DM1. New formulations have improved safety and exposure, with key data readouts expected in 2026–2027. Cash runway extends into 2029.
Design Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
DT-818 for DM1 will enter clinical trials in 2026, with promising preclinical results and broad tissue targeting. DT-216P2 for FA is off clinical hold, with RESTOR-FA data expected in late 2026, and DT-168 for Fuchs is in a novel biomarker study. Cash runway extends into 2029.
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelia...
Design Therapeutics Appoints Justin Gover to Board of Directors
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t...
Design Therapeutics Transcript: Cantor Global Healthcare Conference 2025
GeneTACs are advancing as selective small molecules for monogenic diseases, with clinical progress in Friedreich's ataxia and Fuchs' corneal dystrophy. Improved formulations and biomarker strategies support ongoing trials, and strong financials enable continued development.
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to...
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program
Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
The company is advancing a differentiated small molecule genomic medicine platform with clinical programs in Friedreich ataxia and Fuchs endothelial corneal dystrophy. New formulations address prior safety and exposure issues, with key data readouts expected in 2026.
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; No...
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod...
Design Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025
Gene tag molecules offer a novel approach to modulate gene expression for monogenic diseases, with lead programs DT-216P2 for Friedreich's ataxia and DT-168 for Fuchs' corneal dystrophy advancing in clinical development. Additional pipeline assets target Huntington's and myotonic dystrophy.
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod...
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capit...
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t...
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t...
Design Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025
Multiple gene-targeted programs are advancing, with a new DT-216P2 formulation for Friedreich ataxia addressing prior limitations and aiming for patient studies in mid-2025. Fuchs program phase I data is expected soon, and strong cash reserves support progress into 2029.
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025
Design Therapeutics to Participate in Leerink's Global Healthcare Conference
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t...
Design Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference
DT-216 v2 is set for healthy volunteer studies in early 2025, aiming to address prior safety and exposure issues in FA. The Fuchs program advances with a novel eyedrop and a large observational study, targeting a major unmet need. Both programs are positioned for key data and phase 2 planning in 2025.
Design Therapeutics Transcript: Jefferies London Healthcare Conference 2024
The company is advancing a differentiated genomic medicine platform with four lead programs targeting severe monogenic diseases. Clinical trials for FECD and FA are planned for 2025, supported by a strong cash position and a focus on rapid patient impact.